检索结果-南通市图书馆

Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第45期20卷 17141-17147页

作者： Jia-Zhou Ye Yong-Quan Zhang Hai-Hong Ye Tao Bai Liang Ma bang-de xiang Le-Qun Li department of Hepatobiliary and Pancreas Surgery Affiliated Tumor Hospital of Guangxi Medical University department of Hepatobiliary and Pancreas Surgery Affiliated Minzu Hospital of Guangxi Medical University

AIM: To evaluate the survival benefits of different treatment strategies for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) and to determine the prognosis factors.

关键词： Hepatocellular carcinoma Portal vein tumor thrombosis Conservative treatment Transarterial chemoembolization Surgical resection Postoperative transarterial chemoembolization

Controversies of hepatectomy and adjuvant therapy for hepatocellular carcinoma: moving forward

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatoma Research 2019年第6期5卷 1-6页

作者： Jian-Hong Zhong bang-de xiang department of Hepatobiliary Surgery Affiliated Tumor Hospital of Guangxi Medical UniversityNanning 530021China Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center Nanning 530021China

Due to the prevelence of hepatitis B virus(HBV)and hepatitis C virus(HCV),occurrence of hepatocellular carcinoma(HCC)is increasing in many countries/regions,including China[1].

关键词： hepatocellular adjuvant hepatitis

Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第21期22卷 5088-5095页

作者： Hao-Jie Yang Zhe Guo Yu-Ting Yang Jing-Hang Jiang Ya-Peng Qi Ji-Jia Li Le-Qun Li bang-de xiang department of Hepatobiliary Surgery Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021 Guangxi Zhuang Autonomous Region China department of General Surgery the First People's Hospital of Changde Changde 415000 Hunan Province China department of Oncology the First People's Hospital of Changde Changde 415000 Hunan Province China department of Thyroid and Breast Surgery Central Hospital of Wuhan Wuhan 430000 Hubei Province China department of General Surgery Second People's Hospital of Jingmen Jingmen 448000 Hubei Province China Guangxi Medical University Nanning 530021 Guangxi Zhuang Autonomous Region China

AIM: To investigate whether an elevated preoperative neutrophil-to-lymphocyte ratio(NLR) can predict poor survival in patients with hepatocellular carcinoma(HCC).METHODS: We retrospectively reviewed 526 patients with HCC who underwent surgery between 2004 and ***: Preoperative NLR ≥ 2.81 was an independent predictor of poor disease-free survival(DFS, P decrease had worse survival(DFS, P decrease in NLR than among those showing an increase(DFS, P ded no prognostic information, and so preoperative NLR ≥ 2.81 may be a good complementary indicator of poor OS whenever AFP levels are low or ***: Preoperative NLR ≥ 2.81 may be an indicator of poor DFS and OS in patients with HCC undergoing surgery. Preoperative NLR ≥ 2.81 may be a good complementary indicator of poor OS when elevated AFP levels provide no prognostic information.

关键词： Blood neutrophil-to-lymphocyte ratio Hepatocellular carcinoma Liver resection Prognosis Postoperative change in neutrophil-to-lymphocyte ratio

Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第39期22卷 8798-8805页

作者： Hao-Jie Yang Jing-Hang Jiang Yu-ting Yang xiang-Di Yang Zhe Guo Ya-Peng Qi Feng-Hua Zeng Ke-Lan Zhang Neng-Zhi Chen bang-de xiang Le-Qun Li department of Hepatobiliary Surgery Affiliated Tumor Hospital of Guangxi Medical University department of General Surgery The First People’s Hospital of Changde department of General Surgery Second People’s Hospital of Jing Men department of Chemotherapy Affiliated Tumor Hospital of Guangxi Medical University department of Oncology Chenzhou No.1 People’s Hospital department of Thyroid and Breast Surgery Central Hospital of Wuhan

AIM to determine whether cyclooxygenase-2(COX-2) and prostaglandin E1 receptor(EP1) contribute to disease and whether they help predict *** We retrospectively reviewed the records of 116 patients with hepatocellular carcinoma(HCC) who underwent surgery between 2008 and 2011 at our hospital. Expression of COX-2 and EP1 receptor was examined by immunohistochemistry of formalin-fixed, paraffinembedded tissues using polyclonal antibodies. Possible associations between immunohistochemical scores and survival were *** Factors associated with poor overall survival(OS) were alpha-fetoprotein > 400 ng/m L, tumor size ≥ 5 cm, and high EP1 receptor expression, but not high COX-2 expression. Disease-free survival was not significantly different between patients with low or high levels of COX-2 or EP1. COX-2 immunoreactivity was significantly higher in well-differentiated HCC tissues(Edmondson grade Ⅰ-Ⅱ) than in poorly differentiated tissues(Edmondson grade Ⅲ-Ⅳ)(P = 0.003). EP1 receptor immunoreactivity was significantly higher in poorly differentiated tissue than in well-differentiated tissue(P = 0.001).CONCLUSION COX-2 expression appears to be linked to early HCC events(initiation), while EP1 receptor expression may participate in tumor progression and predict survival.

关键词： Cyclooxygenase-2 Hepatocellular carcinoma Liver resection Prognosis Prostaglandin E1 receptor

Potential Role and Clinical Value of PPP2CA in Hepatocellular Carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2021年第5期9卷 661-671页

作者： Cheng-Lei Yang Xue Qiu Jin-Yan Lin Xiao-Yu Chen Yu-Mei Zhang Xiao-Yin Hu Jian-Hong Zhong Shen Tang Xi-Yi Li bang-de xiang Zhi-Ming Zhang department of Hepatobiliary Surgery Guangxi Medical University Cancer HospitalNanningGuangxiChina The First Clinical Medical School Guangxi Medical UniversityNanningGuangxiChina department of Pathology Guangxi Medical University Cancer HospitalNanningGuangxiChina department of Medical Oncology Affiliated Tumor Hospital of Guangxi Medical UniversityNanningGuangxiChina School of Basic Medical Sciences Guangxi Medical UniversityNanningGuangxiChina School of Public Health Guangxi Medical UniversityNanningGuangxiChina

Background and Aims:Protein phosphatase 2A(PP2A)is associated with many *** study aimed to clarify whether PPP2CA,which encodes the alpha isoform of the catalytic subunit of PP2A,plays a role in hepatocellular carcinoma(HCC)and to identify the potential underlying molecular ***:Based on bioinformatics,public databases and our in-house RNA-Seq database,we analyzed the clinical value and molecular mechanism of PPP2CA in ***:Data were analyzed from 2,545 patients with HCC and 1,993 controls without HCC indexed in The Cancer Genome Atlas database,the Gene Expression Omnibus database and our in-house RNA-Seq ***2CA expression was significantly higher in HCC tissue than in non-cancerous tissues(standardized mean difference:0.69,95%confidence interval[CI]:0.50–0.89).PPP2CA expression was able to differentiate HCC from non-HCC,with an area under the summary receiver operator characteristic curve of 0.79(95%CI:0.75–0.83).Immunohistochemistry of tissue sections confirmed that PPP2CA protein was up-regulated in HCC *** PPP2CA expression in HCC patients was associated with shorter overall,progression-free and disease-free *** molecular pathways through which PPP2CA may be involved in HCC were determined using miRWalk 2.0 as well as analysis of Gene Ontology categories,Kyoto Encyclopedia of Genes and Genomes pathways,and protein-protein interaction ***:PPP2CA is up-regulated in HCC and higher expression correlates with worse ***2CA shows potential as a diagnostic marker for *** studies should examine whether PPP2CA contributes to HCC through the candidate microRNAs,pathways and hub genes identified in this study.

关键词： Hepatocellular carcinoma PPP2CA Molecular mechanism Diagnostic marker

Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第13期22卷 3632-3643页

作者： Hai-Hong Ye Jia-Zhou Ye Zhi-Bo Xie Yu-Chong Peng Jie Chen Liang Ma Tao Bai Jun-Ze Chen Zhan Lu Hong-Gui Qin bang-de xiang Le-Qun Li department of Hepatobiliary Surgery Affiliated Minzu Hospital of Guangxi Medical University department of Hepatobiliary Surgery Affiliated Tumor Hospital of Guangxi Medical University department of Pancreatic Surgery Pancreatic Disease Institute Huashan Hospital Shanghai Medical College Fudan University

AIM: To evaluate the efficacy of transcatheter arterial chemoembolisation (TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma (HCC) in patients with tumor thrombus extending to the main portal ***: From 2009 to 2013, a total of 418 HCC patients with tumor thrombus extending to the main portal vein were enrolled in this study and divided into four groups. These groups underwent different treatments as follows: TACE (n = 307), surgical intervention (n = 54), sorafenib (n = 15) and palliative treatment (n = 42). Overall survival rates were determined by Kaplan-Meier method, and differences between the groups were identified through log-rank analysis. Cox’s proportional hazard model was used to identify the risk factors for ***: The mean survival periods for patients in the TACE, surgical intervention, sorafenib and palliative treatment groups were 10.39, 4.13, 5.54 and 2.82 mo, respectively. For the TACE group, the 3-, 6-, 12- and 24-mo survival rates were 94.1%, 85.9%, 51.5% and 0.0%, respectively. The corresponding rates were 60.3%, 22.2%, 0.0% and 0.0% for the surgical intervention group and 50.9%, 29.5%, 0.0% and 0.0% for the sorafenib group. Evidently, the results in the TACE group were significantly higher than those in the other groups (P 0.05). These values significantly increased after TACE with/without sorafenib compared with other treatments (P < 0.05).CONCLUSION: For HCC patients with tumor thrombus extending to the main portal vein, TACE can yield a higher survival rate than surgical intervention or sorafenib treatment.

关键词： Hepatocellular carcinoma Portal vein Tumor thrombus Sorafenib Transcatheter arterial chemoembolisation Surgery

Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2016年第23期8卷 957-960页

作者： Jian-Hong Zhong Xue-Ke Du bang-de xiang Le-Qun Li department of Hepatobiliary Surgery Affiliated Tumor Hospital of Guangxi Medical University department of Anesthesia Affiliated Tumor Hospital of Guangxi Medical University

Recurrence rate of hepatocellular carcinoma(HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefore it stands to reason to expect that adjuvant sorafenib may improve post-surgery outcomes of patients with HCC. However, many questions still exist about the value of sorafenib for patients with HCC after surgery or transarterial chemoembolization. In this editorial, we complehensively reviewed the safety and efficacy of adjuvant sorafenib for patients with hepatocellar carcinoma after surgery or transarterial chemoembolization. We emphasized the positive and negative role of sorafenib.

关键词： Adjuvant Hepatocellular carcinoma Tumor recurrence Sorafenib

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2016年第13期8卷 605-606页

作者： Jian-Hong Zhong Tian Yang bang-de xiang Le-Qun Li Liang Ma department of Hepatobiliary Surgery Affiliated Tumor Hospital of Guangxi Medical University department of Hepatobiliary Surgery Eastern Hepato-biliary Surgery Hospital Second Military Medical University

Recurrence rate of hepatocellular carcinoma remains quite high even after surgery,and no postoperative therapies have been definitively shown to prevent hepatocellular carcinoma recurrence.A previous study showed that therapy with nucleos(t)ide analogues given to such patients after surgery significantly improved ***,many questions still exist about the usage of nucleos(t)ide analogues for patients with hepatocellular carcinoma after surgery.

关键词： Antiviral therapy Hepatocellular carcinoma Hepatitis B virus Unanswered question

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2013年第3期10卷 158-164页

作者： Yang Ke Liang Ma Xue-Mei You Sheng-Xin Huang Yong-Rong Liang bang-de xiang Le-Qun Li Jian-Hong Zhong Hepatobiliary Surgery department Tumor Hospital of Guangxi Medical University

Objective： To assess the effect of antiviral therapy for hepatitis B virus （HBV）-related hepatocellular carcinoma （HCC） after radical hepatectomy. Methods： A total of 478 HBV-related HCC patients treated by radical hepatectomy were retrospectively collected. Patients in the treatment group （n=141） received postoperative lamivudine treatment （100 rag/d）, whereas patients in the control group （n=337） did not. Recurrence-free survival （RFS） rates, overall survival （OS） rates, treatments for recurrent HCC and cause of death were compared between the two groups. Propensity score matching （PSM） analysis was also conducted to reduce confounding bias between the two groups. Results： The 1-, 3-, and 5-year RFS rates didn＇t significantly differ between the two groups （P=0.778）; however, the 1-, 3-, and 5-year OS rates in the treatment group were significantly higher than those in the control group （P=0.002）. Similar results were observed in the matched data. Subgroup analysis showed that antiviral treatment conferred a significant survival benefit for Barcelona Clinical Liver Cancer stage A/B patients. Following HCC recurrence, more people in the treatment group were able to choose curative treatments than those in the control group （P=0.031）. For cause of death, fewer people in the treatment group died of liver failure than those in the control group （P=0.041）. Conclusion： Postoperative antiviral therapy increases chances of receiving curative treatments for recurrent HCC and prevents death because of liver failure, thereby significantly prolonging OS, especially in early- or intermedian-stage tumors.

关键词： Antiviral therapy hepatocellular carcinoma propensity score matching recurrence-free survival rate